公开(公告)号：WO2010027500A1

公开(公告)日：2010-03-11

申请号：PCT/US2009/005020

申请日：2009-09-08

Applicant: SIGNAL PHARMACEUTICALS, LLC ,  BAHMANYAR, Sogole ,  BATES, R.J. ,  BLEASE, Kate ,  CALABRESE, Andrew, Antony ,  DANIEL, Thomas, Oran ,  DELGADO, Mercedes ,  ELSNER, Jan ,  ERDMAN, Paul ,  FAHR, Bruce ,  FERGUSON, Gregory ,  LEE, Branden ,  NADOLNY, Lisa ,  PACKARD, Garrick ,  PAPA, Patrick ,  PLANTEVIN-KRENITSKY, Veronique ,  RIGGS, Jennifer ,  ROHANE, Patricia ,  SANKAR, Sabita ,  SAPIENZA, John ,  SATOH, Yoshitaka ,  SLOAN, Victor ,  STEVENS, Randall ,  TEHRANI, Lida ,  TIKHE, Jayashree ,  TORRES, Eduardo ,  WALLACE, Andrew ,  WHITEFIELD, Brandon, Wade ,  ZHAO, Jingjing

Inventor： BAHMANYAR, Sogole ,  BATES, R.J. ,  BLEASE, Kate ,  CALABRESE, Andrew, Antony ,  DANIEL, Thomas, Oran ,  DELGADO, Mercedes ,  ELSNER, Jan ,  ERDMAN, Paul ,  FAHR, Bruce ,  FERGUSON, Gregory ,  LEE, Branden ,  NADOLNY, Lisa ,  PACKARD, Garrick ,  PAPA, Patrick ,  PLANTEVIN-KRENITSKY, Veronique ,  RIGGS, Jennifer ,  ROHANE, Patricia ,  SANKAR, Sabita ,  SAPIENZA, John ,  SATOH, Yoshitaka ,  SLOAN, Victor ,  STEVENS, Randall ,  TEHRANI, Lida ,  TIKHE, Jayashree ,  TORRES, Eduardo ,  WALLACE, Andrew ,  WHITEFIELD, Brandon, Wade ,  ZHAO, Jingjing

IPC: C07D471/04 ,  A61K31/437 ,  A61P35/00 ,  A61P5/00 ,  A61P25/00 ,  A61P9/00 ,  A61P19/00 ,  A61P29/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: Provided herein are Heteroaryl Compounds of formula (I): wherein R 1 and R 2 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing inflammatory conditions or cancer, and conditions treatable or preventable by inhibition of a kinase or a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a subject in need thereof.

Abstract translation: 本文提供了式（I）的杂芳基化合物：其中R 1和R 2如本文所定义，包含有效量的杂芳基化合物的组合物和用于治疗或预防炎性病症或癌症的方法，以及可通过抑制激酶治疗或预防的病症 或激酶途径，其包括向有需要的受试者施用有效量的杂芳基化合物。

公开(公告)号：WO2004035061A1

公开(公告)日：2004-04-29

申请号：PCT/EP2003/011380

申请日：2003-10-14

Applicant: NOVARTIS AG ,  NOVARTIS PHARMA GMBH ,  SLOAN, Victor

Inventor： SLOAN, Victor

IPC: A61K31/663

CPC classification number: A61K31/675 ,  A61K31/663

Abstract: Bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, can be used with satisfactory results for treatment of RA by intermittent administration, wherein the periods between bisphosphonate administrations are from about 2 months up to about 4 months, e.g. once every 3 months.

Abstract translation: 可以使用二膦酸盐，特别是更有效的N-二膦酸盐如唑来膦酸和衍生物，其具有满意的结果，用于通过间歇给药治疗RA，其中双膦酸盐施用之间的时间段为约2个月至约4个月，例如。 每3个月一次。

公开(公告)号：WO2014071158A1

公开(公告)日：2014-05-08

申请号：PCT/US2013/068009

申请日：2013-11-01

Applicant: CELGENE CORPORATION ,  WASHINGTON UNIVERSITY ,  SLOAN, Victor, Schorr ,  HRUSKA, Keith ,  FANG, Yifu

Inventor： SLOAN, Victor, Schorr ,  HRUSKA, Keith ,  FANG, Yifu ,  SUNG, Victoria ,  STEVENS, Randall ,  SMITH, William

IPC: A61K38/00 ,  A61K38/29 ,  A61P19/08 ,  A61P19/10 ,  A61K38/22 ,  A61K38/27

CPC classification number: A61K38/1796 ,  A61K38/179

Abstract: Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification.

Abstract translation: 本文提供了用于治疗与肾脏疾病相关的骨病症的方法，其中所述方法包括向需要治疗的受试者施用Activin-ActRIIA抑制剂。 本文还提供了用于治疗低周转性骨疾病的方法和组合物，其中所述方法包括向需要治疗的受试者施用Activin-ActRIIA抑制剂。 本文还提供了用于治疗与肾脏疾病相关的骨疾病的组合物和用于治疗低周转性骨病和血管钙化的组合物。

公开(公告)号：WO0220090A9

公开(公告)日：2003-10-30

申请号：PCT/EP0110448

申请日：2001-09-10

Applicant: NOVARTIS AG ,  NOVARTIS PHARMA GMBH ,  BATEMAN SIMON DAVID ,  GIMONA ALBERTO ,  HOLINEJ JURIJ ,  HUELS JASPER ,  JAYAWARDENE SUMEDHA ,  KARABELAS ARGERIS JERRY ,  KHALED MAHA Y ,  KARNACHI ANEES ABDULQUADAR ,  NIC LOCHLAINN EIMEAR MAIRIN ,  MACERATA RICHARD ,  SLOAN VICTOR

Inventor： BATEMAN SIMON DAVID ,  GIMONA ALBERTO ,  HOLINEJ JURIJ ,  HUELS JASPER ,  JAYAWARDENE SUMEDHA ,  KARABELAS ARGERIS JERRY ,  KHALED MAHA Y ,  KARNACHI ANEES ABDULQUADAR ,  NIC LOCHLAINN EIMEAR MAIRIN ,  MACERATA RICHARD ,  SLOAN VICTOR

IPC: A61K47/02 ,  A61K9/20 ,  A61K9/28 ,  A61K31/195 ,  A61K31/196 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61P5/00 ,  A61P29/00 ,  A61P43/00

CPC classification number: A61K31/195 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2866 ,  A61K31/196

Abstract: A composition for treating a cyclooxygenase-2 dependent disorder or condition comprising: 5-methyl-2(2'-chloro-6'-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, which composition is an immediate release pharmaceutical composition for treatment of said disorder or condition for about 24 hours.

Abstract translation: 一种用于治疗环氧合酶-2依赖性病症或病症的组合物，其包含：5-甲基-2（2'-氯-6'-氟苯胺基）苯乙酸或其药学上可接受的盐，该组合物是用于治疗 所述疾病或病症约24小时。

公开(公告)号：WO2002020090A3

公开(公告)日：2002-03-14

申请号：PCT/EP2001/010448

申请日：2001-09-10

Applicant: NOVARTIS AG ,  NOVARTIS PHARMA GMBH ,  BATEMAN, Simon, David ,  GIMONA, Alberto ,  HOLINEJ, Jurij ,  HUELS, Jasper ,  JAYAWARDENE, Sumedha ,  KARABELAS, Argeris, Jerry ,  KHALED, Maha, Y. ,  KARNACHI, Anees, Abdulquadar ,  NIC LOCHLAINN, Eimear, Mairin ,  MACERATA, Richard ,  SLOAN, Victor

Inventor： BATEMAN, Simon, David ,  GIMONA, Alberto ,  HOLINEJ, Jurij ,  HUELS, Jasper ,  JAYAWARDENE, Sumedha ,  KARABELAS, Argeris, Jerry ,  KHALED, Maha, Y. ,  KARNACHI, Anees, Abdulquadar ,  NIC LOCHLAINN, Eimear, Mairin ,  MACERATA, Richard ,  SLOAN, Victor

IPC: A61P5/00

Abstract: A composition for treating a cyclooxygenase-2 dependent disorder or condition comprising: 5-methyl-2(2'-chloro-6'-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, which composition is an immediate release pharmaceutical composition for treatment of said disorder or condition for about 24 hours.

公开(公告)号：WO0220090A2

公开(公告)日：2002-03-14

申请号：PCT/EP0110448

申请日：2001-09-10

Applicant: NOVARTIS AG ,  NOVARTIS ERFIND VERWALT GMBH ,  BATEMAN SIMON DAVID ,  GIMONA ALBERTO ,  HOLINEJ JURIJ ,  HUELS JASPER ,  JAYAWARDENE SUMEDHA ,  KARABELAS ARGERIS JERRY ,  KHALED MAHA Y ,  KARNACHI ANEES ABDULQUADAR ,  NIC LOCHLAINN EIMEAR MAIRIN ,  MACERATA RICHARD ,  SLOAN VICTOR

Inventor： BATEMAN SIMON DAVID ,  GIMONA ALBERTO ,  HOLINEJ JURIJ ,  HUELS JASPER ,  JAYAWARDENE SUMEDHA ,  KARABELAS ARGERIS JERRY ,  KHALED MAHA Y ,  KARNACHI ANEES ABDULQUADAR ,  NIC LOCHLAINN EIMEAR MAIRIN ,  MACERATA RICHARD ,  SLOAN VICTOR

IPC: A61K47/02 ,  A61K9/20 ,  A61K9/28 ,  A61K31/195 ,  A61K31/196 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61P5/00 ,  A61P29/00 ,  A61P43/00

CPC classification number: A61K31/195 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2866 ,  A61K31/196

Abstract: A composition for treating a cyclooxygenase-2 dependent disorder or condition comprising: 5-methyl-2(2'-chloro-6'-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, which composition is an immediate release pharmaceutical composition for treatment of said disorder or condition for about 24 hours.

Abstract translation: 一种用于治疗环氧合酶-2依赖性病症或病症的组合物，其包含：5-甲基-2（2'-氯-6'-氟苯胺基）苯乙酸或其药学上可接受的盐，该组合物是用于治疗 所述疾病或病症约24小时。